Proteome-wide epitope mapping identifies a resource of antibodies for SARS-CoV-2 detection and neutralization
Te Liang, Mengli Cheng, Fei Teng and 7 more
Signal Transduction and Targeted Therapy · 2021
doi:10.1038/s41392-021-00573-9 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Since December 2019, the coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has become a worldwide pandemic. 1 Significant efforts have been made to generate antibodies to help study COVID-19 pathogenesis, perform diagnostic testing, and develop treatment to neutralize SARS-CoV-2 activity. However, the specific sequence of amino acids recognized and bound by an antibody, the “epitope” is unknown for most antibodies. In this study, we developed a high-throughput epitope mapping platform using a peptide-based SARS-CoV-2 proteome microarray. 2 to detect the binding epitopes of 57 commercial antibodies to ORF1ab, nucleocapsid (N), spike (S), envelop (E), membrane (M), ORF3a, ORF6, ORF7a, and ORF8 proteins (Supplementary Table S1 ).
Abstract licence: CC BY-NC-ND
References5
- 3.
4 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.